Author:
Saif Muhammad Wasif,Sarantopoulos John,Patnaik Amita,Tolcher Anthony W.,Takimoto Chris,Beeram Murali
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference12 articles.
1. Shionoya M, Jimbo T, Kitagawa M, Soga T, Tohgo A (2003) DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo. Cancer Sci 94:459–466
2. Tohgo A, Shionoya M, Iwahana M, Uesugi Y, Jimbo T, Soga T (2002) DJ-927, a novel orally active taxane: 1. Preclinical antitumor activity and toxicity profile. Proceedings of the AACR 43:790 (Abstract 3916)
3. Chan S, Paridaens R, Awada A, Mukherjee A, Lawton P, Dumez H et al (2004) Efficacy and prediction of response to the new oral taxane DJ-927 in anthacycline pre-treated advanced breast cancer (ABC). Eur J Cancer Suppl 4 (No.12):193 (Abstract 641)
4. Evans T, Dobrila R, Berardi R, Sumpter KA, Wall LR, Oyama R et al (2006) A Phase II study of DJ-927 as second-line therapy in patients (pts) with advanced gastric cancer (GC) who have failed a 5-FU non taxane based regimen. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I. 24 (No. 18S) (Abstract 4081)
5. Moore MR, Jones C, Harker G, Lee F, Ardalan B, Saif MW et al (2006) Phase II trial of DJ-927, an oral tubulin depolymerization inhibitor, in the treatment of metastatic colorectal cancer. J Clin Oncol ASCO Annual Meeting Proceedings Part I. 24 (No. 18S) (Abstract 3591)
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献